CORRIGENDUM

doi:10.1038/nature14304

Corrigendum: Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer

Jae Myoung Suh, Johan W. Jonker, Maryam Ahmadian, Regina Goetz, Denise Lackey, Olivia Osborn, Zhifeng Huang, Weilin Liu, Eiji Yoshihara, Theo H. van Dijk, Rick Havinga, Weiwei Fan, Yun-Qiang Yin, Ruth T. Yu, Christopher Liddle, Annette R. Atkins, Jerrold M. Olefsky, Moosa Mohammadi, Michael Downes & Ronald M. Evans

Nature **513**, 436–439 (2014); doi:10.1038/nature13540

This Letter should have declared the following competing financial interests: “The fibroblast growth factor (FGF) molecules and related methods of use reported in this study are covered in the following published patent applications and counterparts that derive priority: (1) PCT/US2011/032848, held by R.M.E., M.D., J.W.J., and J.M.S. (handled by Salk OTD); (2) PCT/US2013/044589, held by M.M., R.G., R.M.E., M.D. and J.M.S. (handled by NYU Office of Industrial Liaison/Technology Transfer); (3) PCT/US2013/044594, held by M.M., R.G., R.M.E., M.D. and J.M.S. (handled by NYU Office of Industrial Liaison/Technology Transfer); and (4) PCT/US2013/044592, held by M.M. and R.G. (handled by NYU Office of Industrial Liaison/Technology Transfer).”.